FDA Clears Ranibizumab for Myopic Choroidal Neovascularization FDA Clears Ranibizumab for Myopic Choroidal Neovascularization
Ranibizumab becomes the first FDA-approved anti-vascular endothelial growth factor therapy for mCNV.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 6, 2017 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news
FDA approves Lucentis (ranibizumab injection) for myopic choroidal neovascularisation
Roche announced today that the US Food and Drug Administration (FDA) has approved Lucentis ® (ranibizumab injection) 0.5 mg for the treatment of patients with myopic choroidal neovascularisation (mCNV), a complication of severe near-sightedness that can lead to blindness. (Source: Roche Investor Update)
Source: Roche Investor Update - January 6, 2017 Category: Pharmaceuticals Source Type: news
FDA Approves Genentech ’s Lucentis (ranibizumab) for Myopic Choroidal Neovascularization
South San Francisco, CA -- January 5, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis ® (ranibizumab injection) 0.5 mg for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 5, 2017 Category: Drugs & Pharmacology Source Type: news
Novartis eye drug franchise hit by failed Fovista studies
ZURICH (Reuters) - Novartis's bid to bolster its eye drug portfolio suffered a setback on Monday when it announced combining Lucentis with Fovista in patients with neovascular age-related macular degeneration (nAMD) did not produce better outcomes than treatment with Lucentis alone. (Source: Reuters: Health)
Source: Reuters: Health - December 12, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Ranibizumab Effective for Pigment Epithelial Detachment Ranibizumab Effective for Pigment Epithelial Detachment
Low-dose ranibizumab is effective in treating pigment epithelial detachment in patients with neovascular age-related macular degeneration, a post hoc analysis of the HARBOR study suggests.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 30, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Predicting Anti-VEGF Response in Diabetic Macular Edema Predicting Anti-VEGF Response in Diabetic Macular Edema
Response after 12 weeks of ranibizumab therapy can predict long-term outcomes in diabetic macular edema, a post hoc analysis suggests.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Is Anti-VEGF Monotherapy Best for Diabetic Macular Edema? Is Anti-VEGF Monotherapy Best for Diabetic Macular Edema?
One of the predictors of visual improvement in patients with diabetic macular edema is ranibizumab monotherapy, an analysis of the RESTORE data shows, but not everyone agrees with the findings.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 10, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Laser vs Drugs for Diabetic Retinopathy: Mostly a Toss-Up (CME/CE)
(MedPage Today) -- But Lucentis favored for some outcomes in randomized trial (Source: MedPage Today Ophthalmology)
Source: MedPage Today Ophthalmology - September 6, 2016 Category: Opthalmology Source Type: news
New Data on RTH258 Show Promise New Data on RTH258 Show Promise
A recent phase 1/2 trial shows that RTH258 is a promising alternative to ranibizumab for the treatment of neovascular age-related macular degeneration.Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 24, 2016 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news
New Batches of Ranibizumab Biosimilar Safe, Effective New Batches of Ranibizumab Biosimilar Safe, Effective
Razumab, an Indian biosimilar for ranibizumab, appears to have overcome the high incidence of inflammation with a new manufacturing process, report investigators.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 15, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Ranibizumab T & amp;E cost effective for wet AMD in UK
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 31, 2016 Category: Drugs & Pharmacology Source Type: news
Doc's Dilemma: Lucentis or Avastin?
(MedPage Today) -- A physician weighs the risks and benefits (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 28, 2016 Category: American Health Source Type: news
Eye drug safety: the impact of a Cochrane Review comparing two treatments for macular degeneration
For more than 20 years, Cochrane has produced systematic reviews of primary research in human health care and health policy. We are internationally recognized as the highest standard in evidence-based healthcare resources.The fourth video in the Cochrane Making a Difference series focuses on the Cochrane Review 'Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration', published in September 2014 from the Cochrane Eyes & Vision Group. The review found that the systemic safety of bevacizumab for macular degeneration appears to be similar to that of ranibizumab - an important co...
Source: Cochrane News and Events - July 1, 2016 Category: Information Technology Authors: nowens at cochrane.org Source Type: news
Aflibercept, ranibizumab are not cost effective in DME
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 30, 2016 Category: Drugs & Pharmacology Source Type: news
Industry Incentives May Drive Pricier Anti-VEGF Drug UseIndustry Incentives May Drive Pricier Anti-VEGF Drug Use
Ophthalmologists with the most and largest payments had highest rates of injection with aflibercept and ranibizumab. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 23, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
